Inhibition of HDAC3 promotes ligand-independent PPARγactivation by protein acetylation

Journal of Molecular Endocrinology

Volumn 53, Issue 2, 2014, Pages 191-200

  Jiang, Xiaoting ^a   Ye, Xin ^a   Guo, Wei ^a,b   Lu, Hongyun ^a,c   Gao, Zhanguo ^a,d  

^a PENNINGTON BIOMEDICAL RESEARCH CENTER   (United States)

^b SHANGHAI UNIVERSITY OF TRADITIONAL CHINESE MEDICINE   (China)

^c THE FIFTH AFFILIATED HOSPITAL OF SUN YAT SEN UNIVERSITY   (China)

^d XINXIANG MEDICAL UNIVERSITY   (China)

Author keywords

Acetylation; Adipocytes; Adipogenesis; HDAC inhibitors; Histone deacetylase; Insulin sensitivity; Metabolic syndrome; Posttranslational modifications; PPAR ; Type 2 diabetes

Indexed keywords

ADIPONECTIN; GLUCOSE; GLUCOSE TRANSPORTER 4; HISTONE DEACETYLASE 3; INSULIN; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PIOGLITAZONE; HISTONE DEACETYLASE; HISTONE DEACETYLASE INHIBITOR; LIGAND;

ACETYLATION; ADIPOCYTE; ADIPOGENESIS; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CELL DIFFERENTIATION; CONTROLLED STUDY; ENZYME ACTIVATION; ENZYME ACTIVITY; ENZYME INHIBITION; FOOD INTAKE; GENE TARGETING; GLUCOSE BLOOD LEVEL; GLUCOSE TRANSPORT; HUMAN; HUMAN CELL; IMMUNOPRECIPITATION; INSULIN RESISTANCE; INSULIN SENSITIVITY; INSULIN TOLERANCE TEST; LIPID DIET; LIPID STORAGE; MALE; MOUSE; NONHUMAN; OBESITY; PROADIPOCYTE; PROTEIN ACETYLATION; PROTEIN DEGRADATION; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PHOSPHORYLATION; PROTEIN PROCESSING; SIGNAL TRANSDUCTION; SUMOYLATION; TRANSCRIPTION INITIATION; WESTERN BLOTTING; ANIMAL; CELL LINE; DRUG EFFECTS; METABOLISM;

ACETYLATION; ADIPOCYTES; ADIPOGENESIS; ANIMALS; CELL LINE; GLUCOSE; HISTONE DEACETYLASE INHIBITORS; HISTONE DEACETYLASES; HUMANS; INSULIN RESISTANCE; LIGANDS; MALE; MICE; PPAR GAMMA;

EID: 84907976646     PISSN: 09525041     EISSN: 14796813     Source Type: Journal    
DOI: 10.1530/JME-14-0066     Document Type: Article

References (43)

1. Anbalagan M, Huderson B, Murphy L & Rowan BG 2012 Post-translational modifications of nuclear receptors and human disease. Nuclear Receptor Signaling 10 e001. (doi:10.1621/nrs.10001)
2. Bardai FH, Price V, Zaayman M, Wang L & D’Mello SR 2012 Histone deacetylase (HDAC1) is a molecular switch between neuronal survival and death. Journal of Biological Chemistry 287 35444-35453. (doi:10.1074/jbc.M112.394544)
3. Berger J & Moller DE 2002 The mechanisms of action of PPARs. Annual Review of Medicine 53 409-435. (doi:10.1146/annurev.med.53.082901.104018)
4. Bhaskara S, Chyla BJ, Amann JM, Knutson SK, Cortez D, Sun ZW & Hiebert SW 2008 Deletion of histone deacetylase 3 reveals critical roles in S phase progression and DNA damage control. Molecular Cell 30 61-72. (doi:10.1016/j.molcel.2008.02.030)
5. Blander G & Guarente L 2004 The SIR2 family of protein deacetylases. Annual Review of Biochemistry 73 417-435. (doi:10.1146/annurev.biochem.73.011303.073651)
6. γagonists: time for a reassessment. Trends in Endocrinology and Metabolism 23 205-215. (doi:10.1016/j.tem.2012.03.001)
7. Chou DH, Holson EB, Wagner FF, Tang AJ, Maglathlin RL, Lewis TA, Schreiber SL & Wagner BK 2012 Inhibition of histone deacetylase 3 protects b cells from cytokine-induced apoptosis. Chemistry & Biology 19 669-673. (doi:10.1016/j.chembiol.2012.05.010)
8. Christianson JL, Nicoloro S, Straubhaar J & Czech MP 2008 Stearoyl-CoA desaturase 2 is required for peroxisome proliferator-activated receptor g expression and adipogenesis in cultured 3T3-L1 cells. Journal of Biological Chemistry 283 2906-2916. (doi:10.1074/jbc.M705656200)
9. Escaffit F, Vaute O, Chevillard-Briet M, Segui B, Takami Y, Nakayama T & Trouche D 2007 Cleavage and cytoplasmic relocalization of histone deacetylase 3 are important for apoptosis progression. Molecular and Cellular Biology 27 554-567. (doi:10.1128/MCB.00869-06)
10. γand adipocyte differentiation. Developmental Cell 3 903-910. (doi:10.1016/S1534-5807(02)00360-X)
11. Ferrara A, Lewis JD, Quesenberry CP Jr, Peng T, Strom BL, Van Den Eeden SK, Ehrlich SF & Habel LA 2011 Cohort study of pioglitazone and cancer incidence in patients with diabetes. Diabetes Care 34 923-929. (doi:10.2337/dc10-1067)
12. γin adipocytes. Journal of Biological Chemistry 277 4062-4068. (doi:10.1074/jbc.M108473200)
13. Freedman LP 1999 Increasing the complexity of coactivation in nuclear receptor signaling. Cell 97 5-8. (doi:10.1016/S0092-8674(00)80708-4)
14. Fujiki K, Kano F, Shiota K & Murata M 2009 Expression of the peroxisome proliferator activated receptor g gene is repressed by DNA methylation in visceral adipose tissue of mouse models of diabetes. BMC Biology 7 38. (doi:10.1186/1741-7007-7-38)
15. Gao Z, Hwang D, Bataille F, Lefevre M, York D, Quon MJ & Ye J 2002 Serine phosphorylation of insulin receptor substrate 1 by inhibitor kB kinase complex. Journal of Biological Chemistry 277 48115-48121. (doi:10.1074/jbc.M209459200)
16. Gao Z, Zhang X, Zuberi A, Hwang D, Quon MJ, Lefevre M & Ye J 2004 Inhibition of insulin sensitivity by free fatty acids requires activation of multiple serine kinases in 3T3-L1 adipocytes. Molecular Endocrinology 18 2024-2034. (doi:10.1210/me.2003-0383)
17. Gao Z, Chiao P, Zhang X, Lazar MA, Seto E, Young HA & Ye J 2005 Coactivators and corepressors of NF-kB in IkBa gene promoter. Journal of Biological Chemistry 280 21091-21098. (doi:10.1074/jbc.M500754200)
18. Gao Z, He Q, Peng B, Chiao PJ & Ye J 2006 Regulation of nuclear translocation of HDAC3 by IkBa is required for tumor necrosis factor inhibition of peroxisome proliferator-activated receptor g function. Journal of Biological Chemistry 281 4540-4547. (doi:10.1074/jbc.M507784200)
19. Gao Z, Yin J, Zhang J, Ward RE, Martin RJ, Lefevre M, CefaluWT& Ye J 2009 Butyrate improves insulin sensitivity and increases energy expenditure in mice. Diabetes 58 1509-1517. (doi:10.2337/db08-1637)
20. Geiss-Friedlander R & Melchior F 2007 Concepts in sumoylation: a decade on. Nature Reviews Molecular Cell Biology 8 947-956. (doi:10.1038/nrm2293)
21. Graves RA, Tontonoz P & Spiegelman BM 1992 Analysis of a tissue-specific enhancer: ARF6 regulates adipogenic gene expression. Molecular and Cellular Biology 12 1202-1208. (doi:10.1128/MCB.12.3.1202)
22. Gregoire S, Xiao L, Nie J, Zhang X, Xu M, Li J, Wong J, Seto E & Yang XJ 2007 Histone deacetylase 3 interacts with and deacetylates myocyte enhancer factor 2. Molecular and Cellular Biology 27 1280-1295. (doi:10.1128/MCB.00882-06)
23. γin adipocytes. Genes and Development 19 453-461. (doi:10.1101/gad.1263305)
24. Hauser S, Adelmant G, Sarraf P, Wright HM, Mueller E & Spiegelman BM 2000 Degradation of the peroxisome proliferator-activated receptor g is linked to ligand-dependent activation. Journal of Biological Chemistry 275 18527-18533. (doi:10.1074/jbc.M001297200)
25. γ. Science 274 2100-2103. (doi:10.1126/science.274.5295.2100)
26. Hu X, Li Y & Lazar MA 2001 Determinants of CoRNR-dependent repression complex assembly on nuclear hormone receptors. Molecular and Cellular Biology 21 1747-1758. (doi:10.1128/MCB.21.5.1747-1758.2001)
27. Huang EY, Zhang J, Miska EA, Guenther MG, Kouzarides T & Lazar MA 2000 Nuclear receptor corepressors partner with class II histone deacetylases in a Sin3-independent repression pathway. Genes and Development 14 45-54. (doi:10.1621/nrs.10001)
28. Krogsdam AM, Nielsen CA, Neve S, Holst D, Helledie T, Thomsen B, Bendixen C, Mandrup S & Kristiansen K 2002 Nuclear receptor corepressor-dependent repression of peroxisome-proliferator-activated receptor d-mediated transactivation. Biochemical Journal 363 157-165. (doi:10.1042/0264-6021:3630157)
29. γ2 transcription through the sumoylated CEBPD in hepatic lipogenesis. Biochimica et Biophysica Acta 1783 1803-1814. (doi:10.1016/j.bbamcr.2008.06.008)
30. γ. International Journal of Obesity 29 (Suppl 1) S10-S12. (doi:10.1038/sj.ijo.0802906)
31. Naya FJ & Olson E 1999 MEF2: a transcriptional target for signaling pathways controlling skeletal muscle growth and differentiation. Current Opinion in Cell Biology 11 683-688. (doi:10.1016/S0955-0674(99)00036-8)
32. γ. Nature 437 759-763. (doi:10.1038/nature03988)
33. γ. Cell 150 620-632. (doi:10.1016/j.cell.2012.06.027)
34. Rosen CJ 2010 Revisiting the rosiglitazone story-lessons learned. New England Journal of Medicine 363 803-806. (doi:10.1056/NEJMp1008233)
35. Rosen ED & Spiegelman BM 2000 Molecular regulation of adipogenesis. Annual Review of Cell and Developmental Biology 16 145-171. (doi:10.1146/annurev.cellbio.16.1.145)
36. Rosen ED, Walkey CJ, Puigserver P & Spiegelman BM 2000 Transcriptional regulation of adipogenesis. Genes and Development 14 1293-1307. (doi:10.1101/gad.14.11.1293)
37. γin metabolic disease. FEBS Letters 585 2121-2128. (doi:10.1016/j.febslet.2011.05.007)
38. γ. Annual Review of Biochemistry 77 289-312. (doi:10.1146/annurev.biochem.77.061307.091829)
39. Treuter E, Albrektsen T, Johansson L, Leers J & Gustafsson JA 1998 A regulatory role for RIP140 in nuclear receptor activation. Molecular Endocrinology 12 864-881. (doi:10.1210/mend.12.6.0123)
40. Tseng CH 2012 Pioglitazone and bladder cancer in human studies: is it diabetes itself, diabetes drugs, flawed analyses or different ethnicities? Journal of the Formosan Medical Association 111 123-131. (doi:10.1016/j.jfma.2011.10.003)
41. Yang XJ & Gregoire S 2006 A recurrent phospho-sumoyl switch in transcriptional repression and beyond. Molecular Cell 23 779-786. (doi:10.1016/j.molcel.2006.08.009)
42. Ye J 2011 Challenges in drug discovery for thiazolidinedione substitute. Yao Xue Xue Bao 1 137-142. (doi:10.1016/j.apsb.2011.06.011)
43. Zamir I, Zhang J & Lazar MA 1997 Stoichiometric and steric principles governing repression by nuclear hormone receptors. Genes and Development 11 835-846. (doi:10.1101/gad.11.7.835)